Detalles de la búsqueda
1.
Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants.
Antimicrob Agents Chemother
; 68(1): e0078123, 2024 Jan 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38038460
2.
Asian participants' experience in phase 3/3b studies of long-acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96.
HIV Med
; 25(3): 381-390, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38147871
3.
Efficacy, safety, and pharmacokinetics by BMI category in Phase 3/3b cabotegravir + rilpivirine long-acting trials.
J Infect Dis
; 2023 Dec 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38134313
4.
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
Clin Infect Dis
; 77(10): 1423-1431, 2023 11 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37340869
5.
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
Clin Infect Dis
; 76(9): 1646-1654, 2023 05 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36660819
6.
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
N Engl J Med
; 382(12): 1124-1135, 2020 03 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-32130806
7.
Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy.
HIV Med
; 24(2): 202-211, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35945163
8.
Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials.
HIV Med
; 24(5): 568-579, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36411596
9.
Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine.
Antimicrob Agents Chemother
; 66(3): e0170221, 2022 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34978890
10.
Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects.
Br J Clin Pharmacol
; 88(10): 4607-4622, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35695476
11.
Multiparametric magnetic resonance imaging to characterize cabotegravir long-acting formulation depot kinetics in healthy adult volunteers.
Br J Clin Pharmacol
; 88(4): 1655-1666, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34240449
12.
Multicompartmental pharmacokinetic evaluation of long-acting cabotegravir in healthy adults for HIV preexposure prophylaxis.
Br J Clin Pharmacol
; 88(4): 1667-1678, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34240467
13.
Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults.
J Antimicrob Chemother
; 75(3): 648-655, 2020 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31873746
14.
Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine.
Ther Adv Infect Dis
; 10: 20499361231214626, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38107552
15.
Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial.
AIDS Patient Care STDS
; 37(1): 53-59, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36626155
16.
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Lancet HIV
; 10(9): e566-e577, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37567205
17.
HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study.
Antimicrob Agents Chemother
; 56(2): 995-1000, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22123685
18.
Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials.
J Acquir Immune Defic Syndr
; 91(2): 157-161, 2022 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36094481
19.
Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study.
J Int AIDS Soc
; 25(9): e26006, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36097674
20.
Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiveness study (CUSTOMIZE).
J Int AIDS Soc
; 25(9): e26003, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36094142